Sign In
Buy INMB
$1.32
-0.1000 (-7.04%)
At Close: Jun 03, 2026
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
04:05pm, Thursday, 31'st Oct 2024
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that har
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
08:00am, Monday, 28'th Oct 2024
“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET.
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
03:03pm, Thursday, 24'th Oct 2024
Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
09:30am, Thursday, 24'th Oct 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-sta
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
08:30am, Friday, 11'th Oct 2024
Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation an
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
05:04am, Monday, 30'th Sep 2024
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
08:00am, Thursday, 26'th Sep 2024
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional
INmune Bio Announces $13.0 Million Registered Direct Offering
08:30am, Friday, 13'th Sep 2024
Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developi
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
09:00am, Tuesday, 03'rd Sep 2024
Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments t
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
11:50pm, Thursday, 01'st Aug 2024
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscien
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
04:05pm, Thursday, 01'st Aug 2024
Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation an
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: IN
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
08:00am, Thursday, 25'th Jul 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
08:45am, Tuesday, 23'rd Jul 2024
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics
